The company said the studies demonstrate the diagnostic, which is an antibody fragment labeled with technetium-99m, can be used to detect the spread of colorectal cancer...CEA-Scan has been submitted for approval in the U.S., Canada and Europe as a diagnostic for the disease. * Perkin-Elmer Corp., of Norwalk, and the National Center for Genome Resources, which houses a U.S.- government sponsored DNA sequence data base in Santa Fe, N.M., have entered into a collaboration to develop software for

It is designed to attach to the beta-glucan receptor on the surface of white blood cells to boost their response to pathogens. * Immunomedics Inc., of Morris Plains, N.J., said pilot clinical trials of its humanized mouse monoclonal antibody for cancers with the carcinoembryonic antigen (CEA) demonstrated the drug had low immunogenicity and high specific binding to the disease targets

Connective Therapeutics Inc., of Palo Alto, Calif., said Phase I studies of recombinant human relaxin for scleroderma showed the agent to be safe...PRO 2000 is designed to block the binding of gp120, a glycoprotein found on the surface of HIV, to the CD4 protein. (c) 1997 American Health Consultants

LMIs are combinations of isolated tumor antigens and cell-size microspheres, which are injected in cancer patients and are designed to stimulate tumor- specific cytotoxic T lymphocytes. * Ligand Pharmaceuticals Inc., of San Diego, and Allergan Ligand Retinoid Therapeutics Inc. (ALRT) settled their patent battle with La Jolla Cancer Research Foundation, of La Jolla, Calif., and SRI International, of Menlo Park, Calif...patents on retinoid technology licensed to Ligand and ALRT by the Salk Institute

The most advanced form, Vistide, is administered intravenously and Gilead expects to file a new drug application for the product with the FDA by the end of 1995. * ID Biomedical Corp., of Vancouver, British Columbia, said stock options exercised by employees and members of the board of directors for 548,000 common shares yielded $5.5 million Canadian (about $4 million U.S.) to the company. * ImmunoGen Inc., of Cambridge, Mass., raised $3.6 million through the sale of subordinated convertible

The company said the placement is part of an agreement to sell up to 9.7 million restricted shares and warrants for another 5 million shares during the third quarter. * LeuKoSite Inc., of Cambridge, Mass., expanded its 1994 collaboration with Warner-Lambert Co., of Morris Plains, N.J., to develop small molecule inhibitors of chemokines, which are believed to be involved in inflammatory and autoimmune diseases

29, 1995 to determine whether fenfluramine and its isomers should be removed from the federal list of controlled substances. * PerSeptive Biosystems Inc., of Farmingham, Mass., said the U.S. District Court in Boston accepted settlement of a class action shareholder lawsuit against the company...The suit was filed in 1994 after PerSeptive was forced to recalculate a series of quarterly financial statements...The takeover was announced in July. (See BioWorld Today Special News Bulletin, July 10, 1995

A designation as a combination product, based on the product's glycerol content, would have required Osteotech to conduct clinical studies. * Protein Polymer Technologies Inc., of San Diego, said holders of its Series C preferred stock provided the company with a $500,000 bridge loan. (c) 1997 American Health Consultants

GeneMedicine Inc., of The Woodlands, Texas, and Medi-Ject Corp., of Minneapolis, are collaborating to develop needle-free injection devices to enhance the delivery of genes to certain tissues. * HemaSure Inc., of Marlborough, Mass., registered to sell 2.5 million shares of common stock. * Mycogen Corp., of San Diego, and Ciba-Geigy Ltd.'s Seed Division, of Greensboro, N.C., received Environmental Protection Agency approval to market seeds for corn hybrids that are genetically engineered to

The drug uses a CD4 protein to attract the virus and remove it from the bloodstream

The company's lead compound, Synovir, whose generic name is thalidomide, is for HIV, cachexia associated with AIDS, cancer and rheumatoid arthritis. * CellPro Inc., of Seattle, said a federal district court jury in Delaware has decided that the company's Ceprate SC Stem Cell Concentration System and its Ceprate LC Laboratory Cell Separation System do not infringe patents held by Johns Hopkins University, of Baltimore, and licensed to Becton Dickinson and Co., of Franklin Lakes, N.J., and Baxter

to certain technology for the use of paclitaxel in the treatment of rheumatoid arthritis and similar conditions. * MDS Health Group Ltd., of Toronto, purchased Panlabs International Inc., a Seattle-based contract research organization. * Oncogene Science Inc., of Uniondale, N.Y., completed the sale of its Research Products Business to Calbiochem- Novabiochem International Inc., of San Diego, for $6 million and other considerations. * Alteon Inc., of Ramsey, N.J., adopted a stockholder rights

OncorMed has exclusive worldwide rights to HCI's hereditary database and added exclusive worldwide commercialization rights to HCI's DNA library. * Paraxel International Corp., a Boston-based contract research organization, opened offices in Milan, Italy, and Kobe, Japan. * Therexsys Ltd., of Staffordshire, England, signed an agreement with Gryphon Sciences, of South San Francisco, to evaluate Gryphon's chemical ligation technologies in Therexsys' targeted gene-delivery system. * Allelix

It said the move is not in response to specific takeover attempts. * CellPro Inc., of Seattle, was granted the use of the CE marking designating full marketing approval throughout Europe for its Ceprate SC Stem Cell Concentration System...The deal, which is in the option stage, calls for the screening of Neurex's library of synthetic peptides and natural compounds isolated from invertebrate venom fractions for selective insecticidal activity. * Sugen Inc., of Redwood City, Calif., adopted a

The treatment is being made available free to people with Lou Gehrig's disease pending the FDA's review of the company's new drug application...Gilead will get $1.25 million to fund research during the extension. * Celgene Corp., of Warren, N.J., and Johns Hopkins University, of Baltimore, will conduct a pilot preclinical program to assess the potential of thalidomide-related drugs in graft-vs.-host disease. (c) 1997 American Health Consultants

* Ligand Pharmaceuticals Inc., of San Diego, launched the sale of Photofrin, a light-activated drug, in Canada for esophageal cancer and superficial bladder cancer. The company licensed the product from QLT PhotoTherapeutics Inc., of Vancouver, Canada. Photofrin is Ligand's second drug on the market in Canada. The first was Proleukin, which is made by Emeryville, Calif.- based Chiron Corp. (c) 1997 American Health Consultants. All rights reserved.

CPC-211 was designed to reduce accumulation of lactate, which causes brain damage in stroke victims...Texas Biotechnology expects to begin Phase I tests for pulmonary hypertension in early 1996. * The National Organization for Rare Disorders (NORD), of New Fairfield, Conn., said the first 1,250 amyotrophic lateral sclerosis patients were chosen to receive Rilutek, a drug made by Rhone-Poulenc Rorer Inc., of Collegeville, Pa

The Immune Response Corp., of Carlsbad, Calif., received FDA clearance to test its psoriasis therapy in a Phase II trial. * Protein Design Labs Inc., of Mountain View, Calif., began a Phase II trials of its monoclonal antibody for treatment of cytomegalovirus (CMV) retinitis in AIDS patients...In addition, Johns Hopkins University and the National Eye Institute will conduct a separate Phase II/III trial with the monoclonal antibody for CMV in AIDS patients. * Rhone-Poulenc Rorer Inc., of

EnzyMed Inc., of Iowa City, which uses enzyme- based combinatorial chemistry to create libraries of organic molecules, entered a research collaboration with DuPont Agricultural Products, a subsidiary of the Wilmington, Del.-based E.I. Du Pont & Co...Terms were not disclosed. * GenPharm International Inc., of Mountain View, Calif., sold its transgenic laboratory products division to Taconic Farms Inc., of Germantown, N.Y. Terms were not disclosed...Progenitor is a subsidiary of Interneuron